Ruchika Talwar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ruchika Talwar has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Brian D. Cortese
Department of Urology, Vanderbilt University Medical Center, Nashville, TN
4 shared publications Thomas J. Guzzo
4 shared publicationsBrian D. Cortese
Department of Urology, Vanderbilt Health, Nashville, Tennessee
3 shared publicationsDaniel J. Lee
Division of Urology, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia
3 shared publicationsJustin Ziemba
Division of Urology, University of Pennsylvania, Philadelphia, Pennsylvania
3 shared publicationsLeilei Xia
Division of Urology, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia
3 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 13 (6) , 578
Editorial Commentary
- 1 November 2026
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 13 (6) , 578
Editorial Commentary
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (11) , 2015-2023
Temporal Association of US Tobacco Taxation on Smoking Attributable Bladder Cancer Mortality and Disability-Adjusted Life Years
PURPOSE: The causal link between smoking and bladder cancer (BC) development is well established but the long-term impact of tobacco taxation and health policy on BC mortality and disability-adjusted life years (DALYs) has not been fully elucidated. Given the protracted latency of carcinogenesis, this study examines whether historical changes in tobacco taxation and smoke-free laws are associated with reductions in BC disease burden and mortality in the United States. METHODS: Smoking-attributable BC mortality and DALY data, and federal and state tobacco taxation data were differenced as time series to achieve stationarity. Cross-correlation analysis identified optimal lag times. A semilogarithmic multivariable linear regression was used to estimate the percent change in BC outcomes per 1% increase in tobacco tax. Analyses were adjusted for national health expenditures and stratified by state. RESULTS: The median lag time between tobacco tax changes and smoking-attributable BC mortality was 17 years, whereas the lag to DALYs was 24 years. National-level regression showed no significant association between taxation and BC mortality (–0.09%, P = .64) or DALYs (1.77%, P = .051). However, 22 states exhibited significant reductions in mortality, with the greatest observed in Arkansas (–3.64%, P < .001), California, and Indiana. Sixteen states showed significant DALY reductions, led by California (–4.68%). The implementation of smoke-free laws alone was not associated with decreases in smoking-attributable BC mortality and DALY. CONCLUSION: Tobacco taxation is significantly associated with long-term reductions in smoking-attributable BC mortality and DALYs at the state level, but not nationally. These findings demonstrate the importance of adjunctive localized public health policy and the delayed impact of tobacco control measures on cancer outcomes. Further investigation is warranted to understand the mechanisms driving state-level variability and to inform targeted prevention strategies.
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (11) , 2015-2023
Temporal Association of US Tobacco Taxation on Smoking Attributable Bladder Cancer Mortality and Disability-Adjusted Life Years
PURPOSE: The causal link between smoking and bladder cancer (BC) development is well established but the long-term impact of tobacco taxation and health policy on BC mortality and disability-adjusted life years (DALYs) has not been fully elucidated. Given the protracted latency of carcinogenesis, this study examines whether historical changes in tobacco taxation and smoke-free laws are associated with reductions in BC disease burden and mortality in the United States. METHODS: Smoking-attributable BC mortality and DALY data, and federal and state tobacco taxation data were differenced as time series to achieve stationarity. Cross-correlation analysis identified optimal lag times. A semilogarithmic multivariable linear regression was used to estimate the percent change in BC outcomes per 1% increase in tobacco tax. Analyses were adjusted for national health expenditures and stratified by state. RESULTS: The median lag time between tobacco tax changes and smoking-attributable BC mortality was 17 years, whereas the lag to DALYs was 24 years. National-level regression showed no significant association between taxation and BC mortality (–0.09%, P = .64) or DALYs (1.77%, P = .051). However, 22 states exhibited significant reductions in mortality, with the greatest observed in Arkansas (–3.64%, P < .001), California, and Indiana. Sixteen states showed significant DALY reductions, led by California (–4.68%). The implementation of smoke-free laws alone was not associated with decreases in smoking-attributable BC mortality and DALY. CONCLUSION: Tobacco taxation is significantly associated with long-term reductions in smoking-attributable BC mortality and DALYs at the state level, but not nationally. These findings demonstrate the importance of adjunctive localized public health policy and the delayed impact of tobacco control measures on cancer outcomes. Further investigation is warranted to understand the mechanisms driving state-level variability and to inform targeted prevention strategies.
- 20 August 2025
- Published by Springer Nature in Nature Reviews Urology
- Vol. 23 (5) , 283-284
Economic impact of tariffs on healthcare costs in urology
- 20 August 2025
- Published by Springer Nature in Nature Reviews Urology
- Vol. 23 (5) , 283-284
Economic impact of tariffs on healthcare costs in urology
- 1 June 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (16) , 1852-1855
Drug Shortages Demand Action: Policy Changes to Protect Patient Care
- 1 June 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (16) , 1852-1855
Drug Shortages Demand Action: Policy Changes to Protect Patient Care
- 25 April 2025
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 35 (4) , 412-417
Cost-effectiveness of serum, urine, and tissue-based prostate cancer biomarkers
Purpose of review: Prostate cancer remains a leading malignancy among men in the United States. While prostate-specific antigen (PSA) screening improves early detection, it also leads to over-diagnosis and over-treatment. Biomarkers offer a promising solution for risk stratification and guiding treatment decisions. This review examines the cost-effectiveness of serum, urine, and tissue-based biomarkers to assess their impact on healthcare expenditures and clinical decision-making. Recent findings: Serum-based biomarkers like 4Kscore and PHI reduce unnecessary biopsies and healthcare costs. Urine-based biomarkers, including SelectMDx and ExoDx Prostate IntelliScore (EPI), have shown potential to optimize prostate cancer detection while being more cost-effective than some serum-based alternatives. Tissue-based biomarkers, such as OncotypeDx and Decipher, help in treatment selection, though their economic impact varies. Economic analyses suggest that biomarkers can enhance clinical decision-making while reducing healthcare expenditures, but real-world validation remains limited. Summary: Prostate cancer biomarkers improve risk stratification and may lower healthcare costs. However, variations in cost-effectiveness, reimbursement policies, and guideline recommendations limit widespread adoption. Prospective studies are needed to validate real-world cost savings and refine biomarker integration into clinical practice. Addressing financial and policy challenges is essential to ensure equitable access and maximize their impact on prostate cancer management.
- 25 April 2025
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 35 (4) , 412-417
Cost-effectiveness of serum, urine, and tissue-based prostate cancer biomarkers
Purpose of review: Prostate cancer remains a leading malignancy among men in the United States. While prostate-specific antigen (PSA) screening improves early detection, it also leads to over-diagnosis and over-treatment. Biomarkers offer a promising solution for risk stratification and guiding treatment decisions. This review examines the cost-effectiveness of serum, urine, and tissue-based biomarkers to assess their impact on healthcare expenditures and clinical decision-making. Recent findings: Serum-based biomarkers like 4Kscore and PHI reduce unnecessary biopsies and healthcare costs. Urine-based biomarkers, including SelectMDx and ExoDx Prostate IntelliScore (EPI), have shown potential to optimize prostate cancer detection while being more cost-effective than some serum-based alternatives. Tissue-based biomarkers, such as OncotypeDx and Decipher, help in treatment selection, though their economic impact varies. Economic analyses suggest that biomarkers can enhance clinical decision-making while reducing healthcare expenditures, but real-world validation remains limited. Summary: Prostate cancer biomarkers improve risk stratification and may lower healthcare costs. However, variations in cost-effectiveness, reimbursement policies, and guideline recommendations limit widespread adoption. Prospective studies are needed to validate real-world cost savings and refine biomarker integration into clinical practice. Addressing financial and policy challenges is essential to ensure equitable access and maximize their impact on prostate cancer management.
- Open Access
- 16 October 2024
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 5 (5) , 312-319
Urologic Cancer Drug Costs in Low- and Middle-Income Countries
All 189 World Bank member countries are classified by their capita gross national income into one of four income groups. In this review, we aim to explore the economic burden and management of urologic oncology conditions in low- and middle-income countries (LMICs), emphasizing disparities and challenges in treatment access. The current World Bank classification system highlights economic stratification, showing significant health outcome disparities, particularly in urologic oncology conditions including kidney, bladder, and prostate cancer. First, this review focuses on the management of advanced prostate cancer in Asian LMICs, revealing higher mortality-to-incidence ratios and a greater prevalence of metastatic disease compared to high-income countries (HICs). The prohibitive costs of novel hormonal therapies (NHTs) like abiraterone and enzalutamide limit their use and exacerbate outcome disparities. Second, we review Wilms tumor treatment with chemotherapy in African countries, noting significant price variations for adapted and non-adapted regimens across different economic settings. The cost of chemotherapy agents, particularly dactinomycin, acts as a primary driver of treatment expenses, underscoring the economic challenges in providing high-quality care. Lastly, bladder cancer treatment costs in Brazil and Middle Eastern countries are examined, highlighting how detrimental the economic burden of intravesical therapies, like mitomycin C and Bacillus Calmette–Guérin (BCG), is on treatment accessibility. Overall, this literature review emphasizes the financial strain on healthcare systems and patients, particularly in regions facing economic instability and drug shortages, and underscores the need for international cooperation and effective resource allocation to address the economic barriers to urologic care in LMICs, aiming to improve health outcomes and ensure equitable access to advanced treatments.
- 16 October 2024
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 5 (5) , 312-319
Open AccessUrologic Cancer Drug Costs in Low- and Middle-Income Countries
All 189 World Bank member countries are classified by their capita gross national income into one of four income groups. In this review, we aim to explore the economic burden and management of urologic oncology conditions in low- and middle-income countries (LMICs), emphasizing disparities and challenges in treatment access. The current World Bank classification system highlights economic stratification, showing significant health outcome disparities, particularly in urologic oncology conditions including kidney, bladder, and prostate cancer. First, this review focuses on the management of advanced prostate cancer in Asian LMICs, revealing higher mortality-to-incidence ratios and a greater prevalence of metastatic disease compared to high-income countries (HICs). The prohibitive costs of novel hormonal therapies (NHTs) like abiraterone and enzalutamide limit their use and exacerbate outcome disparities. Second, we review Wilms tumor treatment with chemotherapy in African countries, noting significant price variations for adapted and non-adapted regimens across different economic settings. The cost of chemotherapy agents, particularly dactinomycin, acts as a primary driver of treatment expenses, underscoring the economic challenges in providing high-quality care. Lastly, bladder cancer treatment costs in Brazil and Middle Eastern countries are examined, highlighting how detrimental the economic burden of intravesical therapies, like mitomycin C and Bacillus Calmette–Guérin (BCG), is on treatment accessibility. Overall, this literature review emphasizes the financial strain on healthcare systems and patients, particularly in regions facing economic instability and drug shortages, and underscores the need for international cooperation and effective resource allocation to address the economic barriers to urologic care in LMICs, aiming to improve health outcomes and ensure equitable access to advanced treatments.
- 14 October 2024
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 12 (1) , 101-102
Editorial Comment
- 14 October 2024
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 12 (1) , 101-102
Editorial Comment